Back to Search
WILLIAM SIMON, D.O.
D.O.
Family Medicine Physician
NPI: 1952352007IndividualAccepts Medicare
Specialties, Licenses & Credentials
Family Medicine PhysicianPrimary
Family Medicine
Code: 207Q00000X
0523854(KS)
Education
KANSAS CITY UNIVERSITY OF MED & BIOSCIENCES, COLLEGE OF OSTEO MED
Class of 1989
Research & Publications (20)
Diastereoselective synthesis of 2,3,6-trisubstituted piperidines.
PMID 19441779·J Org Chem·2009
8-other
Spiro(imidazo[1,2-a]pyrano[2,3-c]pyridine-9-indenes) as inhibitors of gastric acid secretion.
PMID 19026549·Bioorg Med Chem·2009
8-other
The promoter C specific ERalpha isoform is associated with tamoxifen outcome in breast cancer.
PMID 19011961·Breast Cancer Res Treat·2009
8-other
Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells.
PMID 19010240·Transplant Proc·2008
8-other
Detecting emotional expression in face-to-face and online breast cancer support groups.
PMID 18540745·J Consult Clin Psychol·2008
8-other
Accelerator beam data commissioning equipment and procedures: report of the TG-106 of the Therapy Physics Committee of the AAPM.
PMID 18841871·Med Phys·2008
8-other
A prototype quantitative film scanner for radiochromic film dosimetry.
PMID 18383667·Med Phys·2008
8-other
Novel imidazo[1,2-a]pyrazine derivatives as potent reversible inhibitors of the gastric H+/K+-ATPase.
PMID 17964794·Bioorg Med Chem·2008
7-preclinical
Isolation and fractionation of the endoplasmic reticulum from castor bean (Ricinus communis) endosperm for proteomic analyses.
PMID 18369899·Methods Mol Biol·2008
8-other
Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast.
PMID 19077243·BMC Cancer·2008
8-other
5-Substituted 1H-pyrrolo[3,2-b]pyridines as inhibitors of gastric acid secretion.
PMID 17962023·Bioorg Med Chem·2008
7-preclinical
A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer.
PMID 19047159·Cancer Res·2008
8-other
Symptom-oriented follow-up of early breast cancer is not inferior to conventional control. Results of a prospective multicentre study.
PMID 17848816·Onkologie·2007
4-observational
Novel indanyl-substituted imidazo[1,2-a]pyridines as potent reversible inhibitors of the gastric H+/K+-ATPase.
PMID 17723299·Bioorg Med Chem Lett·2007
7-preclinical
Soraprazan: setting new standards in inhibition of gastric acid secretion.
PMID 17369284·J Pharmacol Exp Ther·2007
7-preclinical
Differential proteomic analysis of the endoplasmic reticulum from developing and germinating seeds of castor (Ricinus communis) identifies seed protein precursors as significant components of the endoplasmic reticulum.
PMID 17407185·Proteomics·2007
8-other
Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of patients with primary invasive breast cancer.
PMID 17558308·Pharmacogenet Genomics·2007
8-other
Synthesis and evaluation of 7H-8,9-dihydropyrano[2,3-c]imidazo[1,2-a]pyridines as potassium-competitive acid blockers.
PMID 17975907·J Med Chem·2007
7-preclinical
Preparation of tetrahydroimidazo[2,1-a]isoquinolines and their use as inhibitors of gastric acid secretion.
PMID 17881235·Bioorg Med Chem·2007
8-other
Evaluation of an in vitro model of androgen ablation and identification of the androgen responsive proteome in LNCaP cells.
PMID 17152098·Proteomics·2007
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2131 N RIDGE RD
WICHITA, KS 67212 - Phone
- (316) 773-1212
Quick Facts
- NPI
- 1952352007
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 37
- Publications
- 20
Are you this provider?
Claim Your Profile